These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11178544)

  • 1. Development and prevalidation of alternative methods for the potency testing of C. perfringens vaccines.
    Ebert E; Öppling V; Werner E; Cubetaler K
    ALTEX; 1998; 15(5):59-61. PubMed ID: 11178544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
    Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
    ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and prevalidation of two different ELISA systems for the potency testing of Clostridium perfringens beta and epsilon-toxoid containing veterinary vaccines.
    Ebert E; Oppling V; Werner E; Cussler K
    FEMS Immunol Med Microbiol; 1999 Jul; 24(3):299-311. PubMed ID: 10397315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of the Toxin Neutralisation Test in Mice by in vitro Serological Assay Systems for Potency Testing of Tetanus Toxoid Vaccines for Veterinary Use: Results of a European Collaborative Study.
    Hendriksen CF
    ALTEX; 1994; 11(5):30-34. PubMed ID: 11178404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of Clostridium perfringens vaccines using an indirect competitive ELISA for the epsilon toxin component - examination of the assay by a collaborative study.
    Rosskopf-Streicher U; Volkers P; Werner E
    Pharmeuropa Bio; 2004 Jan; 2003(2):91-6. PubMed ID: 14960265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vitro alternative to the mouse neutralisation assay for potency testing of betatoxoid containing Clostridium, perfringens type B and type C vaccines for veterinary use.
    Ebert E; Kusch M; Öppling V; Werner E; Cussler K
    ALTEX; 1996; 13(2):68-75. PubMed ID: 11178445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interlaboratory validation of in vitro serological assay systems to assess the potency of tetanus toxoid in vaccines for veterinary use.
    Hendriksen CF; Woltjes J; Akkermans AM; van der Gun JW; Marsman FR; Verschure MH; Veldman K
    Biologicals; 1994 Sep; 22(3):257-68. PubMed ID: 7811460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation and establishing of serological methods for the potency testing of immunglobulins against Clostridium tetani-toxin.
    Ebert E; Abu Karim A; Kayser T; Wenig R; Weibetaer K; Wirz M; Pisani G; Schäffner G; Cubetaler K
    ALTEX; 1998; 15(5):30-32. PubMed ID: 11178535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of monoclonal antibodies suitable for use in antigen quantification potency tests for clostridial veterinary vaccines.
    Hauer PJ; Clough NE
    Dev Biol Stand; 1999; 101():85-94. PubMed ID: 10566780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
    Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
    Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collaborative study for the validation of alternative in vitro potency assays for human tetanus immunoglobulin.
    Gross S; Janssen SW; de Vries B; Terao E; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):11-25. PubMed ID: 20144449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collaborative study for the establishment of a European Pharmacopoeia Biological Reference Preparation for Clostridia antiserum for serological potency testing of veterinary clostridial vaccines.
    Lucken R; Daas A; Behr-Gross ME
    Dev Biol (Basel); 2002; 111():171-80. PubMed ID: 12678238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Batch potency testing of inactivated erysipelas vaccines by ELISA--development, validation and implementation.
    Rosskopf-Streicher U; Johannes S; Gyra H; Beckmann R; Cussler K
    Dev Biol (Basel); 2002; 111():153-8. PubMed ID: 12678235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of the in vivo neutralisation test for efficacy demonstration of tetanus vaccines ad us. vet.
    Rosskopf U; Noeske K; Werner E
    ALTEX; 2005; 22(3):169-74. PubMed ID: 16186992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collaborative study for the establishment of erysipelas ELISA coating antigen. European Biological Reference Preparation batch no. 1.
    Cussler K; Rosskopf-Streicher U; Volkers P; Milne C
    Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):75-88. PubMed ID: 11705102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use.
    Winsnes R; Hendriksen C; Sesardic D; Akkermans A; Daas A
    Dev Biol Stand; 1999; 101():277-88. PubMed ID: 10566802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency Testing of Swine Erysipelas Vaccines by Serology Results of a Pre-validation Study.
    Rosskopf-Streicher U; Johannes S; Wilhelm M; Gyra H; Cussler K
    ALTEX; 1999; 16(3):123-128. PubMed ID: 11107318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2.
    Buchheit KH; Daas A
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):95-108. PubMed ID: 12448033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release?
    Poirier B; Variot P; Delourme P; Maurin J; Morgeaux S
    Vaccine; 2010 Feb; 28(7):1796-802. PubMed ID: 20018270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.